Literature DB >> 30654043

Reducing the risk of misdiagnosis of indirect ELISA by normalizing serum-specific background noise: The example of detecting anti-FGFR3 autoantibodies.

Christian P Moritz1, Yannick Tholance2, François Lassablière3, Jean-Philippe Camdessanché4, Jean-Christophe Antoine4.   

Abstract

Indirect enzyme-linked immunosorbent assay (ELISA) is an important diagnostic method as it enables the quantification of the presence of autoantibodies in human blood sera. However, unspecific binding of antibodies to the solid phase causes considerable serum-specific background noise (SSBN), involving the risk of false positive diagnosis. Therefore, we present a simple and concise, yet obvious proof-of-principle of a recently suggested normalization method. The method is based on subtracting SSBN by using non-coated ELISA wells as a control for each serum-of-interest. We performed ELISA to quantify anti-fibroblast growth factor receptor 3 (FGFR3) antibody levels in three positive controls (two anti-FGFR3-positive patients and a rabbit antiserum against FGFR3) and 58 negative controls (healthy blood donors). In all subjects, we found considerable unspecific reactivity which strongly varied among subjects. The conventional normalization method was not able to balance this strong SSBN, as demonstrated by 2/58 false positive healthy controls and one FGFR3-positive patient that was hidden in the noise (false negative). SSBN normalization reduced the frequency of false-positives to 0/58. Further, all three anti-FGFR3-positive sera were successfully detected and even doubled their z-score used to determine positivity. Albeit occupying more space on the ELISA plate, we strongly recommend considering this normalization method when working with blood sera. To better put the idea across to the community, we depict the SSBN issue and its solution in a graphic scheme. We conclude that SSBN normalization increases the sensitivity and specificity of indirect ELISA and thereby reduces the risk of false positive and false negative diagnosis. © 2019. Licensed under the Creative Commons [CC BY-NC 4.0 licence, https://doi.org/10.1016/j.jim.2019.01.004].
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Background noise; ELISA; Misdiagnosis; Normalization; Sensitivity; Specificity; Unspecific

Mesh:

Substances:

Year:  2019        PMID: 30654043     DOI: 10.1016/j.jim.2019.01.004

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  7 in total

1.  Maximum antigen diversification in a lyme bacterial population and evolutionary strategies to overcome pathogen diversity.

Authors:  Lia Di; Saymon Akther; Edgaras Bezrucenkovas; Larisa Ivanova; Brian Sulkow; Bing Wu; Saad Mneimneh; Maria Gomes-Solecki; Wei-Gang Qiu
Journal:  ISME J       Date:  2021-08-19       Impact factor: 10.302

2.  Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020.

Authors:  Ranawaka Apm Perera; Chris Kp Mok; Owen Ty Tsang; Huibin Lv; Ronald Lw Ko; Nicholas C Wu; Meng Yuan; Wai Shing Leung; Jacky Mc Chan; Thomas Sh Chik; Chris Yc Choi; Kathy Leung; Kin Ho Chan; Karl Ck Chan; Ka-Chi Li; Joseph T Wu; Ian A Wilson; Arnold S Monto; Leo Lm Poon; Malik Peiris
Journal:  Euro Surveill       Date:  2020-04

3.  Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections.

Authors:  Huibin Lv; Nicholas C Wu; Owen Tak-Yin Tsang; Meng Yuan; Ranawaka A P M Perera; Wai Shing Leung; Ray T Y So; Jacky Man Chun Chan; Garrick K Yip; Thomas Shiu Hong Chik; Yiquan Wang; Chris Yau Chung Choi; Yihan Lin; Wilson W Ng; Jincun Zhao; Leo L M Poon; J S Malik Peiris; Ian A Wilson; Chris K P Mok
Journal:  Cell Rep       Date:  2020-05-18       Impact factor: 9.423

4.  Clinical features with anti fibroblast growth factor receptor 3 (FGFR3) antibody-related polyneuropathy: a retrospective study.

Authors:  Elanagan Nagarajan; Seung Ah Kang; Carmen Holmes; Raghav Govindarajan
Journal:  BMC Neurol       Date:  2021-02-15       Impact factor: 2.474

5.  An Integrated Platform for Serological Detection and Vaccination of COVID-19.

Authors:  Sung-Chan Wei; Wei-Ting Hsu; Chun-Hsiang Chiu; Feng-Yee Chang; Huei-Ru Lo; Chuan-Yu Liao; Hwai-I Yang; Yu-Chi Chou; Chih-Hsuan Tsai; Yu-Chan Chao
Journal:  Front Immunol       Date:  2021-12-23       Impact factor: 7.561

6.  Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections.

Authors:  Huibin Lv; Nicholas C Wu; Owen Tak-Yin Tsang; Meng Yuan; Ranawaka A P M Perera; Wai Shing Leung; Ray T Y So; Jacky Man Chun Chan; Garrick K Yip; Thomas Shiu Hong Chik; Yiquan Wang; Chris Yau Chung Choi; Yihan Lin; Wilson W Ng; Jincun Zhao; Leo L M Poon; J S Malik Peiris; Ian A Wilson; Chris K P Mok
Journal:  bioRxiv       Date:  2020-03-17

7.  P. falciparum and P. vivax Orthologous Coiled-Coil Candidates for a Potential Cross-Protective Vaccine.

Authors:  Imen Ayadi; Saidou Balam; Régine Audran; Jean-Pierre Bikorimana; Issa Nebie; Mahamadou Diakité; Ingrid Felger; Marcel Tanner; François Spertini; Giampietro Corradin; Myriam Arevalo; Socrates Herrera; Valentina Agnolon
Journal:  Front Immunol       Date:  2020-10-21       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.